294 related articles for article (PubMed ID: 36048467)
1. Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy.
Ding C; Chen C; Zeng X; Chen H; Zhao Y
ACS Nano; 2022 Sep; 16(9):13513-13553. PubMed ID: 36048467
[TBL] [Abstract][Full Text] [Related]
2. Stimuli-Responsive Prodrug Chemistries for Cancer Therapy.
Bargakshatriya R; Pramanik SK
Chembiochem; 2023 Sep; 24(18):e202300155. PubMed ID: 37341379
[TBL] [Abstract][Full Text] [Related]
3. Dimeric prodrug-based nanomedicines for cancer therapy.
Li S; Shan X; Wang Y; Chen Q; Sun J; He Z; Sun B; Luo C
J Control Release; 2020 Oct; 326():510-522. PubMed ID: 32721523
[TBL] [Abstract][Full Text] [Related]
4. Stimuli-responsive prodrug-based cancer nanomedicine.
Xie A; Hanif S; Ouyang J; Tang Z; Kong N; Kim NY; Qi B; Patel D; Shi B; Tao W
EBioMedicine; 2020 Jun; 56():102821. PubMed ID: 32505922
[TBL] [Abstract][Full Text] [Related]
5. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
6. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
7. Block copolymer prodrugs: Synthesis, self-assembly, and applications for cancer therapy.
Dutta D; Ke W; Xi L; Yin W; Zhou M; Ge Z
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1585. PubMed ID: 31452353
[TBL] [Abstract][Full Text] [Related]
8. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in sulfur dioxide releasing nanoplatforms for cancer therapy.
He P; Ren X; Zhang Y; Tang B; Xiao C
Acta Biomater; 2024 Jan; 174():91-103. PubMed ID: 38092251
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticulation of Prodrug into Medicines for Cancer Therapy.
Zhang Y; Cui H; Zhang R; Zhang H; Huang W
Adv Sci (Weinh); 2021 Sep; 8(18):e2101454. PubMed ID: 34323373
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
12. Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials.
Vemula PK; Wiradharma N; Ankrum JA; Miranda OR; John G; Karp JM
Curr Opin Biotechnol; 2013 Dec; 24(6):1174-82. PubMed ID: 23465753
[TBL] [Abstract][Full Text] [Related]
13. Taxanes prodrug-based nanomedicines for cancer therapy.
Sun L; Zhao P; Chen M; Leng J; Luan Y; Du B; Yang J; Yang Y; Rong R
J Control Release; 2022 Aug; 348():672-691. PubMed ID: 35691501
[TBL] [Abstract][Full Text] [Related]
14. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy.
Huang Z; Ding Y; Luo Y; Chen M; Zeng Z; Zhang T; Sun Y; Huang Y; Zhao C
Acta Biomater; 2022 Oct; 152():367-379. PubMed ID: 36084924
[TBL] [Abstract][Full Text] [Related]
15. Prodrug approaches for the development of a long-acting drug delivery systems.
Chien ST; Suydam IT; Woodrow KA
Adv Drug Deliv Rev; 2023 Jul; 198():114860. PubMed ID: 37160248
[TBL] [Abstract][Full Text] [Related]
16. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
Jana S; Mandlekar S; Marathe P
Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
[TBL] [Abstract][Full Text] [Related]
17. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs: design and clinical applications.
Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Järvinen T; Savolainen J
Nat Rev Drug Discov; 2008 Mar; 7(3):255-70. PubMed ID: 18219308
[TBL] [Abstract][Full Text] [Related]
19. Strategies on the development of small molecule anticancer drugs for targeted therapy.
Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
[TBL] [Abstract][Full Text] [Related]
20. NIR light-triggered nanomaterials-based prodrug activation towards cancer therapy.
Zhang F; Wu Q; Liu H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1643. PubMed ID: 32394638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
